Our Company
About Us
Leadership Team
Board of Directors
Advisory Board
Chemoprotection & ALRN-6924
Overview
Role of P53
Preclinical Research
Scientific Publications
Clinical Development
Investors & Media
Careers
Aileron Presents Proof-of-Concept Clinical Data for ALRN-6924 in Late-Breaking Presentation at EORTC-NCI-AACR Symposium
Transforming the Experience of Chemotherapy for Patients
Learn More
What's New at Aileron
Press Releases
Aileron Therapeutics is a clinical stage company developing a novel medicine, ALRN-6924, to improve the outcomes and the quality of life of cancer patients.
Learn More
ALRN-6924 is administered prior to chemotherapy to protect healthy normal cells from negative side effects.
Learn More
Latest News
July 8, 2021
Aileron Therapeutics to Participate in Fireside Chat at the William Blair Biotech Focus Conference 2021
July 1, 2021
Aileron Therapeutics Announces Initiation of Randomized, Double-Blind, Placebo-Controlled Trial of ALRN-6924 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
June 24, 2021
Aileron Therapeutics to be Added to the Russell Microcap® Index
More News
